CD274 and neoplasm: Other trials are ongoing, including a randomized Phase I/II study that combines the PD-L1 blocker avelumab with Radium-233 and M3814, an inhibitor of double-stranded break repair enzymes, with the hypothesis that this may enhance direct tumor killing and immune mobilization (NCT04071236).